TORONTO--(BUSINESS WIRE)--NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), has been named as one of Canada’s Top 10™ Life Science Companies and was also given the award for the Best Company Presentation in the Life Sciences Technologies Stream of the Banff Venture Forum.
